文献速递艾滋病与性传播感染

妊娠期人类免疫缺陷病毒(HIV)-1抗逆转录病毒治疗对妊娠期体重增加的影响

The Effect of Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Pregnancy on Gestational Weight Gain.
PubMed 文献 · Clin Infect Dis · 2022-01-01

一项回顾性队列研究纳入303例接受抗逆转录病毒治疗(ART)的HIV-1感染孕妇,分析不同ART方案与妊娠期体重过度增加的关系。结果显示,与未暴露于整合酶链转移抑制剂(INSTI)或富马酸替诺福韦艾拉酚胺(TAF)者相比,接受INSTI+TAF方案者妊娠期体重过度增加的相对风险(RR)为1.7倍(95%CI:1.18-2.68;P<.01),而接受富马酸替诺福韦二吡呋酯者RR为0.64倍(95%CI:.41-.99;P=.047)。

要点

  • 接受INSTI+TAF方案的孕妇妊娠期体重过度增加风险升高(RR 1.7,95%CI 1.18-2.68;P<.01)。
  • 接受富马酸替诺福韦二吡呋酯者妊娠期体重过度增加风险降低(RR 0.64,95%CI .41-.99;P=.047)。
  • INSTI单独使用与妊娠期体重过度增加无显著关联,各组新生儿、产科及母体结局无差异。

核心结论

  • 接受INSTI+TAF联合方案的HIV-1感染孕妇妊娠期体重过度增加的风险升高。

研究设计与样本

  • 回顾性队列研究,纳入303例接受ART的HIV-1感染孕妇,使用对数线性模型估计不同ART方案类型的相对风险(RR),并校正孕前BMI和基线可检测病毒载量。

主要发现

  • 整个队列中53%的孕妇在孕前已启动ART(P=无显著性)。
  • 队列中29%的孕妇发生妊娠期体重过度增加。
  • 与未暴露于INSTI或TAF者相比,接受INSTI+TAF者妊娠期体重过度增加的RR为1.7倍(95%CI:1.18-2.68;P<.01)。
  • 接受富马酸替诺福韦二吡呋酯者妊娠期体重过度增加的RR为0.64倍(95%CI:.41-.99;P=.047)。
  • INSTI单独使用与体重过度增加无显著关联;未使用INSTI时TAF的效果无法从本数据推断;各组新生儿、产科及母体结局无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gestational weight gain above Institute of Medicine recommendations is associated with increased risk of pregnancy complications. The goal was to analyze the association between newer HIV antiretroviral regimens (ART) on gestational weight gain. METHODS: A retrospective cohort study of pregnant women with HIV-1 on ART. The primary outcome was incidence of excess gestational weight gain. Treatment effects were estimated by ART regimen type using log-linear models for relative risk (RR), adjusting for prepregnancy BMI and presence of detectable viral load at baseline. RESULTS: Three hundred three pregnant women were included in the analysis. Baseline characteristics, including prepregnancy BMI, viral load at prenatal care entry, and gestational age at delivery were similar by ART, including 53% of the entire cohort had initiated ART before pregnancy (P = nonsignificant). Excess gestational weight gain occurred in 29% of the cohort. Compared with non-integrase strand transfer inhibitor (-INSTI) or tenofovir alafenamide fumarate (TAF)-exposed persons, receipt of INSTI+TAF showed a 1.7-fold increased RR of excess gestational weight gain (95% CI: 1.18-2.68; P < .01), while women who received tenofovir disoproxil fumarate had a 0.64-fold decreased RR (95% CI: .41-.99; P = .047) of excess gestational weight gain. INSTI alone was not significantly associated with excess weight gain in this population. The effect of TAF without INSTI could not be inferred from our data. There was no difference in neonatal, obstetric, or maternal outcomes between the groups. CONCLUSIONS: Pregnant women receiving ART with a combined regimen of INSTI and TAF have increased risk of excess gestational weight gain.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Joseph NT, Satten GA, Williams RE, et al. The Effect of Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Pregnancy on Gestational Weight Gain. Clin Infect Dis. 2022. PMID: 34864949. doi:10.1093/cid/ciab994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。